At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 796 enrolled
Drug / intervention
ER niacin/laropiprant +1 moredrug
Likely dose
ER niacin/laropiprant 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating ER niacin/laropiprant and Comparator : placebo (unspecified) for Diabetes Mellitus Type 2. Completed, enrolled 796 participants.
Detailed Summary
A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus Type 2
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartJul 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedJun 13, 2007
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.1 years ago
Interventions
ER niacin/laropiprantdrug
One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
Comparator : placebo (unspecified)drug
ER niacin/laropiprant Placebo